Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial

Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial Publisher Pubmed

Ebrahimi P¹ ; Seyedmirzaei H² ; Moradi K¹ ; Bagheri S¹ ; Moeini M³ ; Mohammadi MR¹ ; Akhondzadeh S¹

Show Affiliations

1. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Iran
2. Interdisciplinary Neuroscience Research Program (INRP), Tehran University of Medical Sciences, Iran
3. Department of Psychology, Faculty of Psychology and Education, Allameh Tabatabaei University, Tehran, Iran

Source: International Clinical Psychopharmacology Published:2023

Abstract

We aimed to evaluate cilostazol therapeutic effects on aberrant behaviors of autism spectrum disorder (ASD) children and its safety profile in a double-blind, randomized clinical trial. Sixty-six children with confirmed ASD were allocated to receive either daily 50-mg cilostazol (increased to 100 mg/day after 2 weeks) or matched placebo in addition to risperidone. The Aberrant Behavior Checklist-Community Edition (ABC-C) scale and a checklist of probable adverse effects were used to assess the behavioral outcomes and safety profile at weeks 0, 5, and 10 of the study. Sixty-one participants, with comparable baseline characteristics, completed the trial. Unlike other ABC-C subscales, repeated-measures analysis showed significant effect for time × treatment interaction in the hyperactivity subscale (P = 0.047; partial eta squared = 0.06). We used the median value for the baseline score hyperactivity subscale [median (interquartile range) = 31 (24-37)] to stratify participants to higher hyperactivity and lower hyperactivity subgroups and found that only participants with higher hyperactivity benefit from cilostazol adjunctive therapy (P = 0.028; partial eta squared = 0.14). Cilostazol could be considered as a safe agent with beneficial effects on hyperactivity in children with ASD and higher levels of hyperactivity. © 2023 Lippincott Williams and Wilkins. All rights reserved.

Related Docs

View other Related Docs

1. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial?, Clinical Neuropharmacology (2020)

2. Prednisolone As Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial, Clinical Neuropharmacology (2020)

3. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)

4. Palmitoylethanolamide As Adjunctive Therapy for Autism: Efficacy and Safety Results From a Randomized Controlled Trial, Journal of Psychiatric Research (2018)

5. Sulforaphane As an Adjunctive Treatment for Irritability in Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2020)

6. Simvastatin As an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)

7. Baclofen As an Adjuvant Therapy for Autism: A Randomized, Double-Blind, Placebo-Controlled Trial, European Child and Adolescent Psychiatry (2019)

8. Effects of Non-Invasive Neurostimulation on Autism Spectrum Disorder: A Systematic Review, Clinical Psychopharmacology and Neuroscience (2020)

Experts (# of related papers)

View all Related Experts

Shahin Akhondzadeh Basti (15)

Mohammad Reza Mohammadi (14)

Style	Citing Format
MLA	Ebrahimi P, et al.. "Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial." International Clinical Psychopharmacology, vol. 38, no. 2, 2023, pp. 89-95.
APA	Ebrahimi P, Seyedmirzaei H, Moradi K, Bagheri S, Moeini M, Mohammadi MR, Akhondzadeh S (2023). Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial. International Clinical Psychopharmacology, 38(2), 89-95.
Chicago	Ebrahimi P, Seyedmirzaei H, Moradi K, Bagheri S, Moeini M, Mohammadi MR, Akhondzadeh S. "Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial." International Clinical Psychopharmacology 38, no. 2 (2023): 89-95.
Harvard	Ebrahimi P et al. (2023) 'Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial', International Clinical Psychopharmacology, 38(2), pp. 89-95.
Vancouver	Ebrahimi P, Seyedmirzaei H, Moradi K, Bagheri S, Moeini M, Mohammadi MR, et al.. Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial. International Clinical Psychopharmacology. 2023;38(2):89-95.
BibTex	@article{ author = {Ebrahimi P and Seyedmirzaei H and Moradi K and Bagheri S and Moeini M and Mohammadi MR and Akhondzadeh S}, title = {Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial}, journal = {International Clinical Psychopharmacology}, volume = {38}, number = {2}, pages = {89-95}, year = {2023} }
RIS	TY - JOUR AU - Ebrahimi P AU - Seyedmirzaei H AU - Moradi K AU - Bagheri S AU - Moeini M AU - Mohammadi MR AU - Akhondzadeh S TI - Cilostazol As Adjunctive Therapy in Treatment of Children With Autism Spectrum Disorders: A Double-Blind and Placebo-Controlled Randomized Trial JO - International Clinical Psychopharmacology VL - 38 IS - 2 SP - 89 EP - 95 PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract